Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Mar;51(3):497-506.
doi: 10.3109/10428190903518337.

Chemokine polymorphisms and lymphoma: a pooled analysis

Paige M Bracci  1 , Christine F Skibola, Lucia Conde, Eran Halperin, Tracy Lightfoot, Alex Smith, Randi A Paynter, Danica R Skibola, Luz Agana, Eve Roman, Eleanor Kane, John K Wiencke
Affiliations

Chemokine polymorphisms and lymphoma: a pooled analysis

Paige M Bracci et al. Leuk Lymphoma. 2010 Mar.

Abstract

Polymorphisms in chemokine genes have been associated with human immunodeficiency virus (HIV)-related non-Hodgkin lymphoma (NHL) but are understudied in non-HIV-related NHL. Associations of NHL and NHL subtypes with polymorphisms and haplotypes in CCR5, CCR2, CCL5, CXCL12, and CX(3)CR(1) were explored in a pooled analysis of three case-control studies (San Francisco Bay Area, California; United Kingdom; total: cases N = 1610, controls N = 1992). Adjusted unconditional logistic regression was used to estimate relative risks among HIV-negative non-Hispanic Caucasians. The CCR5 Delta32 deletion reduced the risk of NHL (odds ratio = 0.56, 95% confidence interval = 0.38-0.83) in men but not women with similar effects observed for diffuse large-cell and follicular lymphoma (FL). NHL risk also was reduced in men with the CCR2/CCR5 haplotype characterized by the CCR5 Delta32 deletion. The CCL5 -403A allele conferred reduced risks of FL and chronic lymphocytic leukemia/small lymphocytic lymphoma. Results should be interpreted conservatively. Continued investigation is warranted to confirm these findings.

PubMed Disclaimer

References

    1. Hartge P, Wang S, Bracci P, Holly E, Devesa S. Non-Hodgkin Lymphoma. In: Schottenfeld D, Fraumeni JJ, editors. Cancer Epidemiology and Prevention. Oxford University Press; New York: 2006.
    1. Skibola CF, Bracci PM, Halperin E, et al. Polymorphisms in the estrogen receptor 1 and vitamin C and matrix metalloproteinase gene families are associated with susceptibility to lymphoma. PLoS One. 2008;3:e2816. - PMC - PubMed
    1. Dean M, Jacobson LP, McFarlane G, et al. Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-delta32 mutation. Cancer Res. 1999;59:3561–4. - PubMed
    1. Rabkin CS, Yang Q, Goedert JJ, Nguyen G, Mitsuya H, Sei S. Chemokine and chemokine receptor gene variants and risk of non-Hodgkin’ s lymphoma in human immunodeficiency virus-1-infected individuals. Blood. 1999;93:1838–42. - PubMed
    1. Oppenheim JJ, Zachariae CO, Mukaida N, Matsushima K. Properties of the novel proinflammatory supergene “intercrine” cytokine family. Annu Rev Immunol. 1991;9:617–48. - PubMed

Publication types